Dr. Sandhya Srinivas, MD
Medical Oncology (Medical Oncology Physician)
300 Pasteur Dr
Stanford, CA 94305
Who else practices at this address →
Santa Clara County includes mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 41
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 372
Licensed in California since 1991, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
CA license A49392 (first issued 1991; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Stanford Health Care Stanford, CA
- Stanford Health Care Tri-Valley Pleasanton, CA
Medical groups
- Stanford Health Care (3,122 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 372
- Services billed
- 1,041
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 717 | 259 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 183 | 44 |
| New patient office or other outpatient visit, 45-59 minutes | 80 | 80 |
| Hospital discharge day management, 30 minutes or less | 33 | 31 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 26 | 26 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Stanford, CA | 31 |
| Dexamethasone Other prescribers in Stanford, CA | 20 |
| Abiraterone Acetate | 19 |
| Bicalutamide | 18 |
| Cabometyx (cabozantinib s-malate) | 15 |
| Ondansetron Hcl Other prescribers in Stanford, CA | 15 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 11 companies reported 23 payments worth $14,497 in total to this clinician.
| Janssen Biotech, Inc. | $4,230 |
|---|---|
| Merck Sharp & Dohme LLC | $3,103 |
| Janssen Research & Development, LLC | $2,300 |
| Astellas Pharma Global Development | $2,100 |
| Janssen Scientific Affairs, LLC | $1,918 |
| Aveo Pharmaceuticals, Inc. | $268 |
| Pfizer Inc. | $176 |
| Exelixis Inc. | $175 |
| Consulting Fee | $12,670 |
|---|---|
| Food and Beverage | $1,163 |
| Travel and Lodging | $663 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Feb 28, 2025 | Consulting Fee | $2,468 |
| Janssen Research & Development, LLC Oct 2, 2025 | Consulting Fee | $2,300 |
| Merck Sharp & Dohme LLC Jul 23, 2025 | Consulting Fee | $2,240 |
| Astellas Pharma Global Development Dec 12, 2025 | Consulting Fee Xtandi · Oncology | $2,100 |
| Janssen Scientific Affairs, LLC Jun 18, 2025 | Consulting Fee ERLEADA · Oncology | $1,800 |
| Janssen Biotech, Inc. Jun 13, 2025 | Consulting Fee ERLEADA · Oncology | $1,763 |
| Merck Sharp & Dohme LLC Apr 8, 2025 | Travel and Lodging ONCOLOGY · travel to Dallas, TX · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $259 |
| Merck Sharp & Dohme LLC Apr 8, 2025 | Travel and Lodging ONCOLOGY · travel to Dallas, TX · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $205 |
| Merck Sharp & Dohme LLC Apr 8, 2025 | Travel and Lodging ONCOLOGY · travel to Dallas, TX · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $156 |
| Merck Sharp & Dohme LLC Apr 23, 2025 | Travel and Lodging ONCOLOGY · travel to Dallas, TX Company’s descriptionProvided as part of a clinical research engagement. | $42.98 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 19 industry-funded studies in 2025, from 11 companies. The companies reported $1,246,333 in research payments for these studies, mostly to the institutions running them.
- A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT05125016 - A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer mCRPC That Progressed On or After Prior Tr…
Merck Sharp & Dohme LLC - A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab MK-3475 Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants with Muscle-invasive Blad…
Merck Sharp & Dohme LLC - A phase 1, multi-center, open-label, dose finding study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cc-94676 in subjects with metastatic castration-resistant prostate cancer
E.r. Squibb & Sons, L.l.c. - A Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with High-Risk, Metastatic Castration-Resistant Prostate Cancer
Exelixis Inc. - A phase 1, multi-center, open-label, dose finding study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cc-94676 in subjects with metastatic castration-resistant prostate cancer
Celgene Corporation - A Phase 1, Open-label Study of BMS-986460 in Participants with Metastatic Castration-resistant Prostate Cancer
E.r. Squibb & Sons, L.l.c. - A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 Plus Pembrolizumab MK-3475 Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Rena…
Merck Sharp & Dohme LLC - MK-5684-003# A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer mCRPC Previously Treated With …
Merck Sharp & Dohme LLC - A phase 3 randomized openlabel study of PF06821497 mevrometostat in combination with enzalutamide compared with enzalutamide or docetaxel in participants with metastatic castration resistant prostate cancer previously…
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.